U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07024160) titled 'Phase I Study of MT1011 Injection in Healthy Subjects' on June 09.
Brief Summary: This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects. Includes 5 dose cohorts, with 40 subjects planned for enrollment.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation
Intervention:
DRUG: MT1011
MT1011 is a novel synthetic small molecule...